CHALLENGE ADVANCES HEALTH TECHNOLOGIES AND MEDICAL DEVICES IN THE MEDTECH SECTOR Building Better Futures for Health Reaches 11 Year Milestone
With
George Sidis, Managing Director,
IDE Group
Teneille Murray,
Innovation & Growth Lead
Medical Technology Association of Australia
Nick Northcott, Co-Founder & Executive Chairman
Eudaemon Technologies
SEGMENT
Filmed in Sydney | August 2026
In July IDE Group launched the 2027 Building Better Futures for Health (BBFH) Challenge, a program supporting early-stage MedTech innovators move from concept to commercialisation. Delivered with Medical Technology Association of Australia’s (MTAA) MedTech Compass, the 2027 program marks 10 years of impact.
Now in its 11th year, BBFH supports researchers, clinicians, entrepreneurs and early-stage ventures tackling urgent healthcare needs. Selected teams will pitch to industry experts, gaining feedback to strengthen commercial potential.
BBFH combines IDE Group’s commercial and technical expertise with MTAA’s sector knowledge to help high-potential innovators validate, develop and commercialise health technologies. Since 2018, it has become a key platform for Australian MedTech innovation.
Participants will compete for up to $40,000 in IDE Group services: a $30,000 jury prize and $10,000 People’s Choice Award. Finalists also receive tailored guidance from IDE Group’s engineers, designers and clinicians.
The winning team will join MedTech Compass, MTAA’s program supporting early-stage medical device and digital health ventures with regulation, reimbursement, investment and market access guidance.
Over the years several start-ups have reached maturation to enter or soon to enter the market such as the inaugural Building Better Futures for Health (BBFH) Winner 2016 Eudaemon Technologies.
Applications close 31 August 2026, followed by a Semi-Finalist Showcase on the 12 November 2026 in Sydney and the Grand Final at the MTAA MedTech Conference on 3 March 2027 in Sydney. To apply, please visit the BBFH Challenge website at www.ide.group/bbfh-challenge.
Source: Adapted from joint IDE Group and MTAA media release, July 2026
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
-
LIVED EXPERIENCE: Spontaneous Coronary Artery Dissection (SCAD)
Jen O’Neill is a Social Work Program Manager and mother of two from the Central Coast, NSW.
At 36, she experienced her first spontaneous coronary artery dissection (SCAD) heart attack and has since survived two further SCADs before age 43.
